Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
Public ClinicalTrials.gov record NCT02009865. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet and lifestyle stabilization and washout period and a 12-week treatment period.
Study identification
- NCT ID
- NCT02009865
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 379 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2013 (Actual)
- Primary completion
- Dec 23, 2014 (Actual)
- Completion
- Dec 23, 2014 (Actual)
- Last update posted
- Sep 10, 2019
2013 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90057 | — |
| Research Site | St. Petersburg | Florida | 33709 | — |
| Research Site | Addison | Illinois | 60101 | — |
| Research Site | Louisville | Kentucky | 40213 | — |
| Research Site | Cincinnati | Ohio | 45227 | — |
| Research Site | Cincinnati | Ohio | 45246 | — |
| Research Site | Columbus | Ohio | 43213 | — |
| Research Site | Kettering | Ohio | 45429 | — |
| Research Site | Lyndhurst | Ohio | 44124 | — |
| Research Site | Oklahoma City | Oklahoma | 73103 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Orangeburg | South Carolina | 29118 | — |
| Research Site | Bristol | Tennessee | 37620 | — |
| Research Site | Houston | Texas | 77074 | — |
| Research Site | Katy | Texas | 77450 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02009865, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2019 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02009865 live on ClinicalTrials.gov.